Elicio Therapeutics, Inc.
ELI-002 7P
metastatic mKRAS pancreatic cancer
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ELI-002 7P in metastatic mKRAS pancreatic cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“03 Inform future development plans in metastatic PDAC, and the adjuvant PDAC Phase 3 trial”